INTRODUCTION
============

Type 2 diabetes mellitus (T2DM) is associated with a 1.5 to 2.5-fold increased risk for dementia, and this trend is similar for both Alzheimer\'s disease (AD) and vascular dementia (VaD), which are the most common subtypes of dementia \[[@B1][@B2]\]. With the increasing numbers of elderly people with T2DM in the general population, dementia is especially important due to its impact on self-management and quality of life. Therefore, identifying modifiable risk factors for dementia is crucial to public health. The mechanisms underlying the association between T2DM and dementia are not fully understood, but they are multifactorial, including poor glucose control, hypoglycemia, inflammatory mediators, and rheological factors \[[@B3]\].

Hypoglycemia is a potentially serious complication during diabetes treatment and it may be an obstacle to optimal glycemic control. As glucose is the primary source of energy for the brain, hypoglycemia may cause mild or severe neurological deficits, including coma \[[@B4][@B5]\]. Although the short-term effects of hypoglycemia on cognitive function have been well documented, it is unclear whether patients with hypoglycemia will develop dementia. A few epidemiological studies have shown that severe hypoglycemia is associated with a greater risk for dementia \[[@B6][@B7][@B8][@B9]\], but others have reported no significant association between hypoglycemia and subsequent dementia \[[@B10][@B11]\]. In addition, because the pathogeneses of AD and VaD are very different, the same hypoglycemic assault may have different effects on the progression of dementia according to subtype. However, previous studies have not estimated dementia risk according to dementia subtype.

Therefore, the purpose of the current study was to investigate the association between hypoglycemia and subsequent dementia in older adults with T2DM by conducting a propensity score matching analysis to minimize selection bias. We also identified the effect of hypoglycemia on dementia according to each subtype. We used the Korean National Health Insurance Service Senior cohort, which contains 14 years of follow-up data for \>10% of all older adults in South Korea.

METHODS
=======

Study design and data source
----------------------------

This study was a population-based retrospective observational study and was approved by the Institutional Review Board of the Korea National Institute for Bioethics Policy (<http://www.irb.or.kr/>, P01-201811-21-008), which waived the requirement for informed consent because all patient data were de-identified.

Data source
-----------

We used the Korean National Health Insurance Service Senior cohort version 3.0 (January 1, 2002 to December 31, 2015), which contains around 550,000 patients (\>10% of the entire South Korea senior population in 2002). This dataset was extracted from the Korean National Health Insurance Service, which covers over 99% of the South Korean population, using a stratified random sampling method with 1,476 strata; thus, it is representative of the entire Korean senior population. This data set included information on the socioeconomic status of Korean National Health Insurance Service recipients; status was based on income and assets, such as property and automobile ownership.

Inclusion and exclusion criteria
--------------------------------

Patients diagnosed with T2DM and prescribed oral hypoglycemic agents or insulin were enrolled ([Fig. 1](#F1){ref-type="fig"}). The index date was January 1, 2011, and patients were divided into two groups according to the presence of hypoglycemia (International Classification of Diseases, 10th revision \[ICD-10\] codes E11.63, E15, E16.0, E16.1, and E16.2) before the index date. Patients who experienced at least one hypoglycemic episode were placed in the hypoglycemia group, which was then divided into three groups according to the number of hypoglycemic episodes (one episode, two or three episodes, or more than three episodes). Patients with type 1 diabetes mellitus (T1DM; ICD-10 code E10) or dementia diagnoses (ICD-10 codes F00, F01, F02, F03, F04, F05, G30, or G31) or a medication prescribed to treat dementia (donepezil, memantin, rivastigmine, or galantamine) before the index date (January 1, 2002 to December 31, 2010) were excluded. The loss of samples is described in [Fig. 1](#F1){ref-type="fig"}. Because the Korean National Health Insurance Service Senior cohort consists of patients ≥60 years old in 2002, all patients were \>68 years of age on the index date.

Study outcome and subgroup analysis
-----------------------------------

The primary outcome was the first diagnosis of all-cause dementia (ICD-10 codes F00, F01, F02, F03, F04, F05, G30, or G31). The secondary outcome was the first diagnosis of AD (F00, G30) or VaD (F01). Additionally, we assessed differences in the risk of dementia according to the number of hypoglycemic episodes by dividing the sample into three groups. Subgroup analyses were performed according to sex, age (\<75 and ≥75 years), and the presence of T2DM microvascular (any diagnosis of diabetic nephropathy, neuropathy, or retinopathy) or macrovascular complications (any diagnosis of stroke, transient ischemic attack, acute myocardial infarction, other ischemic heart disease, and peripheral artery occlusive disease).

Statistical analysis
--------------------

All statistical analyses were performed using R software version 3.3.3 (R Development Core Team, Vienna, Austria) and SAS version 9.4 (SAS Institute, Cary, NC, USA). All values are presented as mean±standard deviation. The differences between patients with and without an underlying hypoglycemic event were adjusted with propensity score matching using the nearest-neighbor technique with a caliper of 0.1 on the probability scale. We set age, sex, socioeconomic status (index date), diagnoses (1 year before the index date), and prescribed drugs (180 days before the index date) as confounding variables (all variables presented in [Table 1](#T1){ref-type="table"}) and those were used to calculate propensity scores. The balance achieved by matching propensity scores was assessed using standardized differences, *t*-tests (age), chi-square tests (all other variables except age and socioeconomic status), and Mantel-Haenszel chi-square tests (socioeconomic status); an absolute standardized difference between groups \<0.1 was considered negligible. After the propensity score matching, a Kaplan-Meier curve and Cox proportional hazards model were used to evaluate the dementia risk of hypoglycemia. Because all confounding variables were adjusted in propensity score matching, 1 minus Kaplan-Meier estimate, and a univariate Cox regression analysis were performed.

RESULTS
=======

In total, 48,521 patients were included in the cohort and 220,385 person-years were considered. After propensity score matching, 5,966 patients comprised both groups. The baseline characteristics of the matched group are presented in [Table 1](#T1){ref-type="table"}; all absolute values of standardized differences were \<0.1; thus, all confounding variables were considered properly adjusted by propensity score matching. The mean follow-up period of the matched pairs was 1,591.1 days.

During the study period, 2,934 patients were newly diagnosed with dementia. The patients with at least one hypoglycemia episode showed an increased risk of all-cause dementia compared with those without hypoglycemia (hazard ratio \[HR\], 1.254; 95% confidence interval \[CI\], 1.166 to 1.349; *P*\<0.001) ([Table 2](#T2){ref-type="table"}, [Fig. 2](#F2){ref-type="fig"}). Patients with underlying hypoglycemia were prone to AD and VaD (HR, 1.264; 95% CI, 1.162 to 1.375, *P*\<0.001 for AD; and HR, 1.286; 95% CI, 1.110 to 1.490; *P*\<0.001 for VaD) ([Table 2](#T2){ref-type="table"}, [Fig. 2](#F2){ref-type="fig"}).

According to number of hypoglycemic episodes, the HRs of dementia were 1.170, 1.201, and 1.358 in patients with one hypoglycemic episode, two or three episodes, and more than three episodes, respectively ([Table 3](#T3){ref-type="table"}).

In the subgroup analysis, patients were divided according to sex, age, or the presence of T2DM microvascular or macrovascular complications. Patients who experienced hypoglycemia showed an increased risk for dementia in all subgroups ([Table 4](#T4){ref-type="table"}).

DISCUSSION
==========

This population-based retrospective cohort study showed that patients with a history of hypoglycemia had a higher risk of dementia using the propensity score matching method with large cohort data. This association was persistent in both the AD and VaD subtypes. Patients who experienced repeated episodes of hypoglycemia had a higher risk of dementia. In the subgroup analysis, hypoglycemia increased the risk for dementia in both sexes with or without T2DM microvascular and macrovascular complications.

This is the first cohort study using the propensity score matching method to minimize selection bias. In addition, this is the first study to estimate dementia risk of hypoglycemia according to the specific dementia subtype. Our study included the largest number of patients who have ever experienced hypoglycemia compared with previous studies.

Our study showed that hypoglycemia increased the risk of dementia by 25.4%, which conflicts with some previous studies. The Fremantle Diabetes Study found no evidence that hypoglycemia contributes to cognitive impairment in older adults with T2DM who had normal cognition at baseline \[[@B10]\]. However, the small sample size and relatively short follow-up duration may have limited the power to detect differences. In the Diabetes Control and Complication Trial on younger adults with T1DM, 40% of the patients experienced at least one hypoglycemic coma or seizure but did not decline cognitively \[[@B11]\]. Although this cohort was followed for 18 years, the mean age of the enrolled patients was 27 years, which was too young to show cognitive impairment. The same assault of hypoglycemia may have different impacts according to the age of the subject population, as levels of hippocampal neurogenesis steadily decrease with age \[[@B12]\]. The conflicting results may be due to differences in the demographics of the study populations.

Consistent with our results, three retrospective studies showed that at least one hypoglycemic episode increases the risk of dementia \[[@B6][@B7][@B9]\]. Additionally, repeated episodes of hypoglycemia were correlated with a higher risk of dementia \[[@B6][@B9]\]. Lin and Sheu \[[@B7]\] showed an increased risk of dementia in subjects with a history of hypoglycemia. However, they adjusted only for age, sex, insulin use, and five comorbidities, and included only 289 patients who had had at least one hypoglycemic episode, which is a relatively small sample size \[[@B7]\]. Another retrospective cohort study using the Kaiser Permanente Northern California Diabetes Registry of around 17,000 patients, with a mean age of 65 years, who were followed for 27 years, showed that one, two, and three or more episodes of hypoglycemia increased the risk of dementia, with HRs of 1.26, 1.80, and 1.94, respectively \[[@B6]\]. However, this cohort involved only approximately 1,500 patients with a hypoglycemic experience and did not control for either economic status, which is among the important risk factors for dementia, or medication use, including class of oral hypoglycemic agent or statins, which can affect dementia \[[@B13][@B14][@B15][@B16][@B17][@B18]\]. The third study, using the Clinical Practice Research Datalink (CPRD), which contains the medical records from 674 general practices in the United Kingdom, showed that hypoglycemia is associated with a higher risk of dementia \[[@B9]\]. Furthermore, the risk of dementia increased with the number of hypoglycemia episodes. However, CPRD is collected from general practice and may be biased relative to our data, which was collected from a primary hospital to a tertiary hospital, and this study also did not compensate for socioeconomic status, or medication use, such as each oral hypoglycemic agent class or statins. Compared to all of these previous studies using Cox proportional hazards models that compensated for insufficient confounding factors and included small numbers of patients with hypoglycemia, we used the propensity score matching method and more than 40 confounding variables, including socioeconomic status, oral hypoglycemic agent class, statin use, and many underlying diseases, and included the largest number of patients with hypoglycemia.

Several possible mechanisms have been suggested from animal studies for how hypoglycemia can cause dementia. Multiple animal and human magnetic resonance imaging studies have reported that severe hypoglycemia with coma can lead to selective neuronal cell death in vulnerable brain regions, such as the cortex and hippocampus \[[@B19]\]. This can lead to a decline in memory. In a rat model, significant learning and memory deficits were identified with behavioral testing 6 weeks after inducing 30 minutes of EEG isoelectricity with severe hypoglycemia, which could be attributed to neuronal death observed in the hippocampus of these animals \[[@B20]\]. In another animal study, prolonged moderate hypoglycemia without coma also caused neuronal damage in the prefrontal medial cortex, piriform cortex, and orbital cortex in rats \[[@B21]\].

Other explanations related to vascular and AD pathology are plausible. Increased adrenaline levels during hypoglycemic events enhance platelet and leucocyte activities, and increase the formation of fibrinogen \[[@B22][@B23]\]. Endothelial function may also be compromised during a hypoglycemic attack \[[@B24]\]. All of these factors contribute to micro- or macro-infarcts in the brain, causing vascular cognitive decline. Several studies have shown a possible link between hypoglycemia and AD pathology. In a study with rat primary cortical astroglial cells, hypoglycemia enhanced the expression of mRNA encoding the β-amyloid precursor protein. In a study with neuroblastoma cells, hypoglycemia induced tau hyperphosphorylation, which can lead to the formation of neurofibrillary tangles \[[@B25]\]. In the present study, a history of hypoglycemia increased both the AD and vascular subtypes of dementia. Although it is common to have a single patient with both AD and VD pathology, these subtypes can be difficult to distinguish. This study suggests that hypoglycemia can be related to both pathomechanisms and may make the brain more vulnerable to both pathologies.

This study had several strengths. First, we investigated the largest senior cohort, which contains all of the claims data for \>10% of the entire elderly population in South Korea for 14 years. Second, we tried to exclude bidirectional effects as much as possible. Dementia is one of the major risk factors for hypoglycemia; thus, dementia and hypoglycemia have a bi-directional effect. All subjects in our study were free of dementia at baseline, as we excluded patients who were diagnosed with dementia or prescribed dementia medications during the 9-year period before the index date, to assess temporality in the relationship. Third, as described above, we minimized selection bias by using propensity score matching with 48 variables, such as demographics, socioeconomic status, medication use, and comorbidities.

However, several limitations should be considered. This was a retrospective analysis, and the claims database lacked results of any measurements, such as glycated hemoglobin or Mini-Mental State Exam scores, which may have influenced the results. Specifically, patients with mild cognitive impairment are more difficult to identify using a claims database without cognitive testing results. Thus, prospective cohort studies that include cognitive function tests to exclude mild cognitive impairment before enrollment are needed to confirm our results. Additionally, we analyzed the incidence of dementia and hypoglycemia according to ICD-10 diagnostic codes; however, there may have been some discrepancies between the medical diagnoses and the diagnostic codes in the claims data. However, a previous study showed that the dementia diagnoses in claims data were quite correct when compared with clinically diagnosed dementia \[[@B26]\]. In addition, because \>99% of South Koreans are registered with National Health Insurance, and the dementia diagnostic codes are mandatory to earn insurance benefits when being prescribed dementia medication, it is highly unlikely that dementia would be found without the relevant diagnostic codes in the claims data. In terms of hypoglycemia, clinicians tend not to record hypoglycemia in actual practice, especially when it is mild, when entering diagnostic codes. Thus, this study is limited by the possibility that we underestimated the incidence of hypoglycemic episodes and were unable to assess the effects of mild hypoglycemia on dementia. Last, because this study only included the South Korean population, the results may not be generalizable to all ethnic groups. The incidence and proportion of dementia subtypes vary among ethnic groups \[[@B27][@B28]\]. Previous studies have shown that the Asian population has a greater proportion of VaD and a lower proportion of AD \[[@B29]\].

In summary, our study indicates that a history of hypoglycemia increases the risk for dementia in older adults with T2DM. This association is consistent for both AD and VaD. Caution is advised when treating T2DM in older individuals with hypoglycemia, to prevent deterioration of their cognitive ability.
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###### Baseline characteristics of propensity score matched patients

![](dmj-44-125-i001)

  Characteristic                            Patients without underlying hypoglycemia   Patients with underlying hypoglycemia   SMD       *P* value
  ----------------------------------------- ------------------------------------------ --------------------------------------- --------- -----------
  Number                                    5,966                                      5,966                                             
  Age, yr                                   75.82±5.34                                 75.82±5.41                              \<0.001   0.947
  Male sex, %                               37.81                                      38.50                                   0.014     0.778
  Socio-economic status                                                                                                        0.042     0.427
   1st to 4th of 11 quantiles               1,628 (27.29)                              1,627 (27.27)                                     
   5th to 8th of 11 quantiles               1,822 (30.54)                              1,860 (31.18)                                     
   9th to 11th of 11 quantiles              2,516 (42.17)                              2,479 (41.55)                                     
  Hypertension                              86.24                                      85.82                                   0.012     0.401
  Dyslipidemia                              58.85                                      59.65                                   0.016     0.394
  Chronic kidney disease                    7.58                                       7.71                                    0.005     0.945
  End-stage renal disease                   3.62                                       4.22                                    0.031     0.473
  Any malignancy                            11.33                                      11.26                                   0.002     0.439
  Migraine                                  4.53                                       4.51                                    0.001     0.654
  Asthma                                    19.18                                      19.01                                   0.004     0.971
  Chronic obstructive pulmonary disease     14.28                                      13.88                                   0.012     0.685
  Connective tissue disease                 5.88                                       6.22                                    0.014     0.828
  Atrial fibrillation                       4.51                                       4.64                                    0.006     0.172
  Heart failure                             8.3                                        8.41                                    0.004     0.945
  Osteoporosis                              25.96                                      26.22                                   0.006     0.699
  Cerebrovascular disease                                                                                                                
   Ischemic stroke                          15.37                                      15.39                                   \<0.001   0.533
   Hemorrhagic stroke                       0.62                                       0.85                                    0.027     0.914
   Transient ischemic attack                4.24                                       3.97                                    0.014     0.608
   Acute myocardial infarction              4.61                                       4.27                                    0.016     0.587
   Other ischemic heart disease             28.43                                      28.03                                   0.009     0.768
   Other heart disease                      22.18                                      21.77                                   0.01      0.826
   Peripheral artery disease                2.77                                       2.63                                    0.008     0.476
  Microvascular complications of diabetes                                                                                                
   Neuropathy                               22.95                                      23.21                                   0.006     0.533
   Nephropathy                              8.95                                       9.34                                    0.013     0.271
   Retinopathy                              20.62                                      20.62                                   \<0.001   0.254
  Alcohol use^a^                            2.83                                       2.65                                    0.011     0.736
  Obesity^a^                                0.02                                       0.03                                    0.011     0.465
  Medication use                                                                                                                         
   Anti-diabetic medicine                                                                                                                
    Metformin                               67.83                                      67.77                                   0.001     0.583
    Sulfonylurea                            73.57                                      72.93                                   0.014     0.254
    Thiazolidinedione                       9.1                                        9.52                                    0.014     0.105
    DPP-4i                                  9.29                                       8.73                                    0.019     0.722
    α-Glucosidase inhibitor                 23.33                                      22.9                                    0.01      0.662
    Meglitinide                             4.76                                       5.43                                    0.03      0.777
    Insulin                                 15.35                                      16.46                                   0.03      0.878
   Anti-hypertensive agent                                                                                                               
    Calcium channel blocker                 35.89                                      35.97                                   0.002     0.446
    ACEI                                    10.46                                      10.81                                   0.011     0.463
    ARB                                     52.46                                      52.03                                   0.009     0.728
    β-Blocker                               18.67                                      18.54                                   0.003     0.573
    α-Blocker                               3.1                                        3.07                                    0.002     0.532
   Diuretics                                33.44                                      33.02                                   0.009     0.473
   Aspirin                                  45.31                                      45.31                                   \<0.001   0.956
   P2Y12 inhibitor                          14.08                                      13.68                                   0.012     0.438
   Warfarin                                 1.91                                       2.15                                    0.017     0.949
   Other antiplatelet                       9.45                                       9.35                                    0.003     0.925
   NOAC                                     0.08                                       0.05                                    0.013     0.705
   Lipid-lowering agent                                                                                                                  
    Statin                                  35.77                                      35.97                                   0.004     0.789
    Fibrate                                 3.4                                        3.3                                     0.006     0.757
    Ezetimibe                               1.42                                       1.51                                    0.007     0.819

Values are presented as mean±standard deviation, number (%), or percentage. The mean±standard deviation standardized difference of all covariates was 1.06%±0.09%.

SMD, standardized mean difference; DPP-4i, dipeptidyl-peptidase IV inhibitor; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor antagonists; NOAC, novel oral anticoagulant.

^a^Confirmed using the International Classification of Diseases (10th revision) diagnosis codes.

###### The risk of dementia in patients with hypoglycemia compared to patients without hypoglycemia
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  Variable               Number   Events   HR      95% CI         *P* value
  ---------------------- -------- -------- ------- -------------- -----------
  All-cause dementia     11,932   2,934    1.254   1.166--1.349   \<0.001
  Alzheimer\'s disease   11,932   2,186    1.264   1.162--1.375   \<0.001
  Vascular dementia      11,932   721      1.286   1.110--1.490   \<0.001

HR, hazard ratio; CI, confidence interval.

###### The risk of dementia according to number of hypoglycemic episodes in patients with and without previous hypoglycemic episode
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  No. of previous hypoglycemic episodes   Number   Events   HR      95% CI         *P* value
  --------------------------------------- -------- -------- ------- -------------- -----------
  1                                       4,622    1,159    1.170   1.043--1.313   0.008
  2--3                                    2,946    550      1.201   1.016--1.421   0.032
  \>3                                     4,354    256      1.358   1.060--1.740   0.016

HR, hazard ratio; CI, confidence interval.

###### Subgroup analyses according to sex, age, and the presence of diabetic microvascular or macrovascular complications
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  Variable                                          Number   Events   HR      95% CI         *P* value
  ------------------------------------------------- -------- -------- ------- -------------- -----------
  Male sex                                          4,553    921      1.180   1.037--1.344   \<0.05
  Female sex                                        7,379    2,013    1.297   1.188--1.416   \<0.001
  Patients aged ≥75 years                           6,210    1,893    1.197   1.093--1.310   \<0.001
  Patients aged \<75 years                          5,722    1,041    1.376   1.217--1.556   \<0.001
  Patients with DM microvascular complications      5,039    1,330    1.312   1.177--1.462   \<0.001
  Patients without DM microvascular complications   6,893    1,604    1.208   1.095--1.332   \<0.001
  Patients with DM macrovascular complications      5,089    1,354    1.226   1.102--1.365   \<0.001
  Patients without DM macrovascular complications   6,843    1,580    1.276   1.155--1.409   \<0.001

HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus.

[^1]: ^\*^Young-Gun Kim and Dong Gyu Park contributed equally to this study as first authors.
